Cargando…
REV1: A novel biomarker and potential therapeutic target for various cancers
Background: REV1 is a member of the translesion synthesis DNA polymerase Y family. It is an essential player in a variety of DNA replication activities, and perform major roles in the production of both spontaneous and DNA damage-induced mutations. This study aimed to explore the role of REV1 as a p...
Autores principales: | Zhu, Ning, Zhao, Yingxin, Mi, Mi, Lu, Yier, Tan, Yinuo, Fang, Xuefeng, Weng, Shanshan, Yuan, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9560673/ https://www.ncbi.nlm.nih.gov/pubmed/36246647 http://dx.doi.org/10.3389/fgene.2022.997970 |
Ejemplares similares
-
Ferroptosis regulator FANCD2 is associated with immune infiltration and predicts worse prognosis in lung adenocarcinoma
por: Ye, Chenyang, et al.
Publicado: (2022) -
Global burden of tracheal, bronchus, and lung cancer attributable to occupational carcinogens in 204 countries and territories, from 1990 to 2019: results from the global burden of disease study 2019
por: Zhang, Yan, et al.
Publicado: (2023) -
NALCN is a potential biomarker and therapeutic target in human cancers
por: He, Jian, et al.
Publicado: (2023) -
Emerging patterns and trends in global cancer burden attributable to metabolic factors, based on the Global Burden of Disease Study 2019
por: Zhang, Yan, et al.
Publicado: (2023) -
NPM1 is a Novel Therapeutic Target and Prognostic Biomarker for Ewing Sarcoma
por: Zhou, Yangfan, et al.
Publicado: (2021)